Navigation Links
Abbott Exercises Its Option to Acquire Ibis Biosciences, a Subsidiary of Isis
Date:12/17/2008

the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.

This press release includes forward-looking statements regarding Isis Pharmaceuticals' business, the financial position and outlook for Isis as well as its Ibis Biosciences subsidiary and the commercial potential of Ibis' technologies and products in development. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2007, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

Private Securities Litigation Reform Act
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.; Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Abbott Named One of the Best Places to Launch a Career by BusinessWeek
2. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
3. Abbott Scientists Create One Molecule With Two Antibody Functions
4. Abbott Named to Science Magazines List of Top Employers in the Biotech and Pharmaceutical Industry
5. Abbotts HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
6. Abbott Declares 336th Consecutive Quarterly Dividend
7. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
8. Abbott to Present at JP Morgan Healthcare Conference
9. Abbott Announces Approval of First Fully Automated Blood Screening Test for HTLV-I/HTLV-II
10. Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
11. Abbott Receives FDA Approval for SIMCOR(R) (Niaspan(R) / simvastatin), a Novel Combination Medicine for Comprehensive Cholesterol Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... 16, 2015 Proove Biosciences , ... of BIO Contest for the 2015 BIO International ... 2015 BIO International Convention will take place June 15-18 ... the Buzz of BIO contest, industry leaders will be ... at the conference. The community voting period began on ...
(Date:4/16/2015)... April 16, 2015 The Council ... the prestigious 2015 Borlaug CAST Communication Award goes ... at Tuskegee University in Alabama. Award nominees must ... public presentations; and/or the use of television, radio, ... three areas. As a specialist in the field ...
(Date:4/16/2015)... ChemRar High Tech ... R&D group, and Lancet, Russian Distribution Company, ... commercialization of new medicines in ... stimulate the innovative development of the Russian ... ,     (Logo: http://photos.prnewswire.com/prnh/20150416/739742-b) , Through ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono today ... Darmstadt, Germany , appointed ... Head of Global Clinical Development.  Dr. Reicin brings ... experience in Oncology and Immunology. She is an ... served as a Vice President in various capacities ...
Breaking Biology Technology:Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3The 2015 Borlaug CAST Communication Award Goes to Channapatna Prakash 2Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3
... 20, 2010) -- Recently, academic debate has been swirling ... the most ubiquitous of phenomena, including photosynthesis, the process ... particular, physicists have suggested that entanglement (the quantum interconnection ... atoms that are separated in physical space) could be ...
... ,, CHANTILLY, Va. , Aug. 6 ... as director of Chemical-Biological Defense Programs.  In this role, Chotani will lead ... U.S. Army and the Office of the Secretary of Defense, as well ... Health and the Centers for Disease Control. , ...
... Thursday, August 5, 2010 at 4:30 p.m. Eastern Time , ... BOTHELL, WA and VANCOUVER , Aug. 5 /PRNewswire-FirstCall/ - ... unaudited financial results for the three and six months ended June 30, 2010 and ... , , ...
Cached Biology Technology:TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 2TASC, Inc. Appoints Rashid Chotani to Lead Chemical-Biological Defense Programs 3OncoGenex Reports Second Quarter Financial Results 2OncoGenex Reports Second Quarter Financial Results 3OncoGenex Reports Second Quarter Financial Results 4OncoGenex Reports Second Quarter Financial Results 5OncoGenex Reports Second Quarter Financial Results 6OncoGenex Reports Second Quarter Financial Results 7OncoGenex Reports Second Quarter Financial Results 8OncoGenex Reports Second Quarter Financial Results 9
(Date:3/26/2015)... The Granite Club, ... club, today announced it has implemented a state-of-the-art access ... for members and staff, while restricting access to authorized ... selected FST,s IMID Access system because it has the ... and staff, in addition to unparalleled security," said ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
(Date:3/23/2015)... 2015   HOYOS Labs , a leading global ... that the Company will demonstrate multiple biometrics-based technologies under ... at Connect:ID on March 23 through 25, 2015, in ... highlight the IEEE Biometric Open Protocol Standard; free biometrics-based ... access control system. BOPS was invented by HOYOS Labs ...
Breaking Biology News(10 mins):Granite Club First Private Club in North America to Implement FST Biometrics Secure Access Solution, as Part of Multi-million Dollar Expansion 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3
... genes are especially challenging because they combine many ... of non-coding elements (introns). During processing, introns are ... a template for proteins called messenger RNA (mRNA). ... of a functional protein or, worse, produce an ...
... Institute of Dental and Craniofacial Research (NIDCR), part of ... new piece to the puzzle of how tumor cells ... abnormal growth, a well-known process called angiogenesis. , As ... Cell, the scientists found that in addition to the ...
... cancer that is based on infection with a specially designed ... has shown promise in clinical trials. Now, new research suggests ... as well. The study, published in the July issue of ... to viral therapy after they have been incubated at an ...
Cached Biology News:Carnegie Mellon University research reveals how cells process large genes 2Carnegie Mellon University research reveals how cells process large genes 3New lead reported in tumor angiogenesis 2New lead reported in tumor angiogenesis 3Elevated temperature enhances success of viral cancer therapy 2
... Kits are based on well-established periodate ... consistent and reproducible. This kit contains ... protein or antibody, including ready-to-use buffers ... Activated HRP is supplied ready-to-use and ...
Convenient 10X buffer concentrate used to maximize binding to the solid phase in microwell ELISA. Formulated to provide optimal pH and ionic strength for binding of antibodies and some antigens. Co...
... 2-color real-time PCR detection system holds 48 x ... array of 48 LEDs independently excites fluorescence (470-500 ... filtered photodiodes detects emitted light (523-543 nm and ... MJ Mini cycler, whose Peltier heat pumps provide ...
... (EMSA) is a powerful tool for evaluating ... shift or gel retardation, the assay is ... to electrophoresis, free DNA will migrate differently ... Chemiluminescent EMSA Kit is a nonradioactive system ...
Biology Products: